urapidil has been researched along with Angor Pectoris in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kozàkovà, M | 1 |
| Marco, J | 1 |
| Heusch, G | 1 |
| Bernies, M | 1 |
| Bossi, IM | 1 |
| Palombo, C | 1 |
| Anguissola, GB | 1 |
| Donatelli, F | 1 |
| Laurent, JP | 1 |
| Gregorini, L | 1 |
1 trial available for urapidil and Angor Pectoris
| Article | Year |
|---|---|
The alpha1-adrenergic blocker urapidil improves contractile function in patients 3 months after coronary stenting: a randomized, double-blinded study.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Double-B | 2004 |